Exploration of IL-17 Inhibitors and Lupus Management in Various Scenarios

This chapter delves into adverse events associated with IL-17 inhibitors, discusses discontinuation rates, ISRs, and IBD occurrences, while also examining studies on lupus related to remission rates in pregnant patients, lupus-thrombocytopenia association, and antiphospholipid antibodies impact. Moreover, it highlights the importance of appropriate lupus management in patients on hemodialysis and cautions against halting lupus therapy for faster hemodialysis access.